Examples of fundamental research topics of interest in SusChEM include the replacement of rare, expensive, and/or toxic chemicals/materials with earth-abundant, inexpensive, and benign chemicals/materials; recycling of chemicals/materials that cannot be replaced; development of non-petroleum based sources of important raw materials; chemicals/materials for food and/or water sustainability; the elimination of waste products and enhancement in efficiencies of chemical reactions and processes; discovery of new separation science that will facilitate recycling and production of valuable chemicals/materials; and development and characterization of low cost, sustainable and scalable-manufactured materials with improved properties.
This program supports theoretical and computational materials research and education in the topical areas represented in DMR programs, including condensed matter physics, polymers, solid-state and materials chemistry, metals and nanostructures, electronic and photonicmaterials, ceramics, and biomaterials. The program supports fundamental research that advances conceptual, analytical, and computational techniques for materials research.
The purpose of this funding opportunity announcement (FOA) is twofold: 1. to accelerate translational and clinical Phase I and II a/b safety and efficacy studies for substantiating measurable functional benefits of probiotic/prebiotic components and/or their combinations; and; 2. to understand the underlying mechanisms of their action(s), and variability in responses to these interventions. This FOA calls for interdisciplinary collaborations across scientific disciplines engaged in microbiome and pro/prebiotic research including, but not limited to: nutritional science, microbiology, virology, microecology and microbiome, genomics, immunology, computational biology, chemistry, bioengineering, as well as integration of omics and computational approaches in DNA technologies. This FOA will not support phase III clinical trials.
This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA NIMH and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of compounds of candidate therapeutics; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents.
*Also listed under R21
In celebrating its 350th anniversary, Merck KGaA, Darmstadt, Germany offers a series of research grants to stimulate innovative research in challenging areas of future importance. Merck KGaA, Darmstadt, Germany intends to provide several research grants of up to EUR 350,000 per year for 3 years in various research areas with the option of extension or expansion.
Grants are offered for research in the following areas:
Healthy Lives / Drug Discovery:
Challenge 1: What is the next game-changing molecule or technology to help cure cancer or autoimmune disease?
Life Reimagined / Synthetic Biology:
Challenge 1: What is the next generation production technology for biologics?
Challenge 2: Can you revolutionize microbiome research?
Materials & Solutions:
Challenge 1: Can you develop a new generation of intelligent materials?
Challenge 2: Can you develop advances in characterization, control and surface chemistry?
Challenge 3: Can you develop better atomic layer processes - from modelling to materials?
Digitalization / Computing:
Challenge 1: How can in-silico research benefit from deep learning or quantum computing?
This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices for clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems into functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be functional biodevices and integrated approaches thoroughly characterized to demonstrate preclinical safety and effective performance in support of specific intended clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.
This Funding Opportunity Announcement (FOA) invites exploratory/developmental applications that propose transformative engineering solutions to technical challenges associated with meaningful development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems essential to the development of functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be proof-of-concept prototype biodevices, dedicated biosensors and associated core technologies that enable development of safe and effective intra-oral biodevices intended for specific clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.
Purpose This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems essential to the development of functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be proof-of-concept prototype biodevices, dedicated biosensors, associated core technologies and integrated approaches that enable development of safe and effective intra-oral biodevices intended for specific clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.
The purpose of this funding opportunity announcement (FOA) is to promote the discovery of novel small molecules that may enhance the ability of the immune system to selectively recognize and attack cancer cells. These small molecules could be further developed into stand-alone immunotherapeutics or synergistic partners for existing therapies, or as chemical probes for the discovery and validation of novel targets involved in anti-tumor immunity. Investigators from multiple scientific disciplines (immuno-oncology, tumor biology, screening technology, medicinal chemistry, and pharmacology) are encouraged to establish collaborative teams to discover and develop novel small molecule immunomodulators for cancer therapy. This FOA encourages the design of research projects that utilize the following phases of discovery research: 1) assay development specifically designed for immuno-oncology targets with the intent to screen for novel small molecule compounds that show potential as either probes or drugs, or as pre-therapeutic leads; 2) screen implementation for immunomodulatory targets to identify initial screening hits (from high throughput target-focused approaches or moderate throughput phenotypic- and fragment-based approaches); 3) hit validation through secondary orthogonal and counter screening assays, and hit prioritization; and 4) hit-to-lead optimization.
The purpose of this funding opportunity announcement (FOA) is to promote the discovery of novel small molecules that may enhance the ability of the immune system to selectively recognize and attack cancer cells. These small molecules could be further developed into stand-alone immunotherapeutics or synergistic partners for existing therapies, or as chemical probes for the discovery and validation of novel targets involved in anti-tumor immunity. Investigators from multiple scientific disciplines (immuno-oncology, tumor biology, screening technology, medicinal chemistry, and pharmacology) are encouraged to establish collaborative teams to discover and develop novel small molecule immunomodulators for cancer therapy. This FOA encourages the design of research projects that utilize the following phases of discovery research: 1) assay development specifically designed for immuno-oncology targets with the intent to screen for novel small molecule compounds that show potential as either probes or drugs, or as pre-therapeutic leads; 2) screen implementation for immunomodulatory targets to identify initial screening hits (from high throughput target-focused approaches or moderate throughput phenotypic- and fragment-based approaches); 3) hit validation through secondary orthogonal and counter screening assays, and hit prioritization; and 4) hit-to-lead optimization.
The goal of this Funding Opportunity Announcement (FOA) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic therapeutic agents that prevent Alzheimer's disease (AD), slow its progression or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry, pharmacokinetics (PK), Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET), efficacy in animal models, formulation development, chemical synthesis under Good Manufacturing Practices (GMP), Investigational New Drug (IND) enabling studies and initial Phase I clinical testing. This program does not support research on basic mechanisms of disease, mechanisms of drug action, development of biomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combinations therapies, or discovery activities such as high throughput screening and hit optimization.
OBJECTIVE: This is an AF Special Topic partnership, please see the above AF Special Topic instructions for further details. A Phase I award will be completed over 3 months with a maximum award of $25K and a Phase II may be awarded for a maximum period of 12 months
DESCRIPTION: Academia is producing disruptive science and technology innovations at an increasingly rapid pace. Hence, rather than utilizing a pre-defined requirements approach, this topic is intended to be an open call for ideas and technologies that may not be currently listed (i.e. the unknown-unknown) under STTR topics, but nonetheless still fit within broad interest areas of the Air Force basic research level. These broad areas (Engineering and Complex Systems, Information and Networks, Physical Sciences, and Chemistry/Biological Sciences) are covered in greater detail at wpafb.af.mil/Welcome/Fact-Sheets/Display/Article/842026.
To be eligible, offeror(s) must be teams that have formed companies and partnered with a university (e.g. university entrepreneurship centers, university technology transfer offices).
The offeror should demonstrate their technical capability by demonstrating a credible and high-potential minimum viable product (MVP) along with a credible plan for developing the prototype to a commercially available solution. This topic is not looking for fully formed products, and it is acceptable if the solutions are earlier stage.
The National Science Foundation (NSF) Directorates for Engineering (ENG) and Geosciences (GEO), the Divisions of Integrative Organismal Systems (IOS) and Environmental Biology (DEB), in the Directorate for Biological Sciences (BIO), the Division of Computer and Network Systems in the Directorate Computer and Information Science and Engineering (CISE/CNS), and the Division of Chemistry (CHE) in the Directorate for Mathematical and Physical Sciences, in collaboration with the US Department of Agriculture National Institute of Food and Agriculture (USDA NIFA) encourage convergent research that transforms existing capabilities in understanding dynamic soil processes, including soil formation, through advances in sensor systems and modeling. The Signals in the Soil (SitS) program fosters collaboration among the two partner agencies and the researchers they support by combining resources and funding for the most innovative and high-impact projects that address their respective missions. To make transformative advances in our understanding of soils, multiple disciplines must converge to produce environmentally-benign novel sensing systems with multiple modalities that can adapt to different environments and collect and transmit data for a wide range of biological, chemical, and physical parameters. Effective integration of sensor data will be key for achieving a better understanding of signaling interactions among plants, animals, microbes, the soil matrix, and aqueous and gaseous components. New sensor networks have the potential to inform models in novel ways, to radically change how data is obtained from various natural and managed (both urban and rural) ecosystems, and to better inform the communities that directly rely on soils for sustenance and livelihood.
The ADDF-Harrington Scholar Program is dedicated to advancing academic discoveries into medicines for Alzheimer's disease and related dementias. This unique award provides funding and committed project support by a team of pharmaceutical industry experts through a collaboration with the Alzheimer's Drug Discovery Foundation (ADDF) and Harrington Discovery Institute. This is a special funding opportunity separate from ADDF's Core Funding Programs.
Average Award
Up to $600,000 over 2 years with dedicated support from a team of industry veterans with capabilities that include medicinal chemistry, pharmacology & toxicology, and business development. The expertise of each team is tailored to the specific needs of the project during the two-year award period.
The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA ().
NIST is soliciting applications from eligible institutions of higher education in the U.S. and its territories that offer two- or four- year degrees in academic science, technology, engineering and mathematics (STEM) disciplines, which include but are not limited to biochemistry, biological sciences, chemistry, computer science, engineering, electronics, materials science, mathematics, nanoscale science, neutron science, physical sciences, physics, and statistics, to establish and manage a program to support collaborative research relationships among NIST staff, undergraduate and graduate students, individuals with bachelor's or master's degrees, post-doctoral fellows, and academic affiliates, and the PREP researchers' academic institutions. These collaborative relationships will include research opportunities at the relevant NIST campuses in Boulder, Colorado (CO) (PREP Boulder), or Gaithersburg, Maryland (MD), and/or Charleston, South Carolina (SC) (PREP Gaithersburg). Eligible applicants may apply to establish and manage a PREP Boulder program or a PREP Gaithersburg program or may apply to establish and manage programs for both.
The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research.
To foster innovative collaborative approaches to research projects that propose novel pairings of investigators from at least two broadly disparate disciplines. The proposal must focus on the collaborative relationship, such that the scientific objectives could not be achieved without the efforts of at least two co-principal investigators and their respective disciplines.
The combination and integration of studies may be inclusive of basic, clinical, population, behavioral, and/or translational research. Projects must include at least one Co-PI from a field outside cardiovascular disease and stroke.
This award is also intended to foster collaboration between established and early- or mid-career investigators.
Applications by existing collaborators are permitted, provided that the proposal is for a new and novel idea or approach that has not been funded before.
Multidisciplinary research broadly related to cardiovascular function, cardiovascular disease, and stroke, or to related clinical, basic science, bioengineering, biotechnology, or public health problems.
Proposals are encouraged from all basic science disciplines as well as epidemiological, behavioral, community and clinical investigations that bear on cardiovascular and stroke problems.
AHA awards are open to the array of academic and health professionals. This includes but is not limited to all academic disciplines (biology, chemistry, engineering, mathematics, technology, physics, etc.) and all health-related professions (physicians, nurses, advanced practice nurses, pharmacists, dentists, physical and occupational therapists, statisticians, nutritionists, behavioral scientists, health attorneys, engineers, etc.).
New information technologies can be envisioned that are based on biological principles and that use biomaterials in the fabrication of devices and components; it is anticipated that these information technologies could enable stored data to be retained for more than 100 years and storage capacity to be 1,000 times greater than current capabilities. These could also facilitate compact computers that will operate with substantially lower power than today's computers. Research in support of these goals can have a significant impact on advanced information processing and storage technologies. This focused solicitation seeks high-risk/high-return interdisciplinary research on novel concepts and enabling technologies that will address the scientific issues and technological challenges associated with the underpinnings of synthetic biology integrated with semiconductor technology. This research will foster interactions among various disciplines including biology, engineering, physics, chemistry, materials science, computer science, and information science that will enable heretofore-unanticipated breakthroughs as well as meet educational goals.
The purpose of the NLA Junior Faculty Research is to encourage scholarly advancement of Junior Faculty in the pursuit of a career related to hyperlipidemia and other lipid disorders in humans. The NLA will fund eligible institutions to provide $70,000 per year in salary support for those actively involved in clinical and/or basic science that provides promise of developing new information in fields of study that could advance the diagnosis and management of lipid disorders such as biochemistry, physiology, or genetics as well as interventions that improve therapy. The institutions eligible shall be nonprofit and offer an environment that would logically support a young faculty member with appropriate equipment, space and experienced faculty for proposed studies. The proposal will identify a specific candidate with training and strong signs of early success in an appropriate area of research and with a plan for developing appropriate experiments or clinical studies.
To be eligible, an applicant is expected to hold or be eligible for a doctoral level degree (PhD, PharmD or MD) prior to the date of the scheduled award. There must be a record of accomplishment in a relevant research area as manifest by publications or a PhD thesis of high quality.
The application for the Basic Science Award may focus on any aspect of lipid metabolism that has relevance to human disease. This may include experiments at the laboratory bench involving structural chemistry, biochemistry, physiology or genetics.
